Earnings summaries and quarterly performance for MANGOCEUTICALS.
Executive leadership at MANGOCEUTICALS.
Board of directors at MANGOCEUTICALS.
Research analysts covering MANGOCEUTICALS.
Recent press releases and 8-K filings for MGRX.
Mangoceuticals Closes $2.5 Million Offering
MGRX
- Mangoceuticals, Inc. (MGRX) closed a registered direct offering and concurrent private placement on December 19, 2025.
- The transactions generated approximately $2.5 million in aggregate gross proceeds for the company.
- The offering involved the sale of 1,930,502 Common Units (or Pre-Funded Units) at an offering price of $1.295 per Common Unit.
- The net proceeds are expected to be used for general corporate purposes and working capital.
Dec 19, 2025, 3:38 PM
Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements
MGRX
- Mangoceuticals, Inc. (MGRX) announced a registered direct offering and concurrent private placement, expecting to generate approximately $2.5 million in aggregate gross proceeds.
- The offering involves the sale of 1,930,502 Common Units (or Pre-Funded Units) at an offering price of $1.295 per Common Unit. Each unit includes either one share of Common Stock or one Pre-Funded Warrant, and one PIPE Common Warrant with an exercise price of $1.4245.
- The Pre-Funded Warrants are immediately exercisable at $0.00001 per warrant share.
- The net proceeds from the offerings are designated for general corporate purposes and working capital.
- The transactions are anticipated to close on or about December 19, 2025, with Aegis Capital Corp. acting as the exclusive placement agent.
Dec 19, 2025, 2:28 PM
Mangoceuticals Announces Partnership with Cube Group for $100 Million Solana-Focused Digital Asset Treasury Strategy
MGRX
New Projects/Investments
Equity Issuance
- Mangoceuticals, Inc. (MGRX) announced a partnership with Cube Group to launch an up to $100 million Solana-focused digital asset treasury (DAT) strategy through its newly formed subsidiary, Mango DAT, LLC, with the Master Services Agreement effective December 17, 2025.
- Cube Group will serve as the asset manager, providing discretionary management of Solana tokens with a focus on annualized SOL staking yields and active management targeting 8-20%.
- Mango DAT, LLC will pay Cube a tiered monthly management fee based on assets under management, a 2% annual management fee on initial deposit and 30-day average NAV, and a minimum monthly fee of $2,500.
- To fund the accumulation of Solana tokens, Mangoceuticals plans to leverage its existing shelf registration statement, potentially through an at-the-market (ATM) equity offering program.
Dec 19, 2025, 12:30 PM
Mangoceuticals Announces $100 Million Solana-Focused Digital Asset Treasury Strategy
MGRX
New Projects/Investments
Revenue Acceleration/Inflection
- Mangoceuticals, Inc. (MGRX) announced an up to $100 million Solana-focused digital asset treasury (DAT) strategy in partnership with Cube Group, through its newly formed subsidiary, Mango DAT, LLC.
- This initiative aims to leverage high-yield opportunities in the Solana ecosystem to drive sustainable, non-dilutive growth for shareholders, with Cube Group appointed as the asset manager.
- The DAT 2.0 strategy targets annualized SOL staking yields of 7-8% APY, with active management targeting 8-20%.
- To fund the accumulation of Solana tokens, the Company plans to leverage its existing shelf registration statement, potentially including an at-the-market (ATM) equity offering program.
Dec 19, 2025, 12:30 PM
Mangoceuticals, Inc. Announces $2.5 Million Registered Direct and Private Placements
MGRX
- Mangoceuticals, Inc. has entered into definitive agreements with institutional investors for a registered direct offering and a concurrent private placement.
- The aggregate gross proceeds to the company from both transactions are expected to be approximately $2.5 million.
- The offering involves the sale of 1,930,502 Common Units (or Pre-Funded Units) at an offering price of $1.295 per Common Unit.
- The company plans to use the net proceeds, along with its existing cash, for general corporate purposes and working capital.
Dec 18, 2025, 1:30 PM
Mangoceuticals clarifies launch of GLP-1 weight-management programs
MGRX
Product Launch
New Projects/Investments
- Mangoceuticals, Inc. (MGRX) launched new weight-management programs, MangoRx Direct and PeachesRx Direct, on November 13, 2025.
- These programs are licensed to issue prescriptions for FDA-approved branded GLP-1 medications, including Zepbound® from Eli Lilly and Wegovy® from Novo Nordisk, through a third-party provider.
- The company clarified it has no direct contractual relationship with Eli Lilly or Novo Nordisk, but facilitates patient access to their medications via established channels.
- The MangoRx Direct and PeachesRx Direct programs are live, offering telehealth and personalized care for $99 per month, with medication costs and fulfillment being separate.
Nov 14, 2025, 12:00 PM
Mangoceuticals Clarifies Launch of GLP-1 Weight-Management Programs
MGRX
Product Launch
New Projects/Investments
- Mangoceuticals (MGRX) has launched new weight-management programs, MangoRx Direct and PeachesRx Direct, which are licensed to issue valid prescriptions for FDA-approved GLP-1 medications, including Eli Lilly's Zepbound and Novo Nordisk's Wegovy, through a third-party provider.
- These programs enable Mangoceuticals' customers to access authentic branded GLP-1 medications via the company's platform for the first time, despite Mangoceuticals having no direct contractual relationship with Eli Lilly or Novo Nordisk.
- The MangoRx Direct and PeachesRx Direct programs are now live, offering telehealth consultations, personalized care plans, and ongoing support for $99 per month (medication cost and fulfillment separate).
Nov 14, 2025, 12:37 AM
Mangoceuticals Partners with Eli Lilly and Novo Nordisk for Obesity Management Programs
MGRX
Product Launch
New Projects/Investments
- Mangoceuticals, Inc. (MGRX) has partnered with Eli Lilly and Novo Nordisk to provide affordable access to Zepbound® and Wegovy® for obesity management.
- The company launched MangoRx Direct and PeachesRx Direct programs, offering virtual consultations and personalized treatment plans via a secure telehealth platform.
- These programs include a $99/month medication management membership, with GLP-1 medications available separately starting at $499 per month through LillyDirect® and NovoCare programs.
- The initiative aims to serve self-pay, uninsured, underinsured, and high-deductible patients, as no insurance is required for participation.
Nov 13, 2025, 12:00 PM
Mangoceuticals, Inc. completes private placement
MGRX
- Mangoceuticals, Inc. completed a private placement on August 26 and August 29, 2025, raising a total of $1,100,000.
- The company issued 709,677 shares of restricted common stock at a price of $1.55 per share to five accredited investors.
- The offering was conducted in reliance on an exemption from registration under federal securities laws, specifically Section 4(a)(2) and/or Rule 506(b) of Regulation D.
- The Subscription Agreements grant the investors piggyback registration rights for a period of one year.
Sep 2, 2025, 8:30 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more